BMO Capital Markets Issues Pessimistic Forecast for …

JPMorgan Chase & Co. Cuts AbbVie (NYSE:ABBV) Price Target ... - MarketBeatABBV News Today | Why did AbbVie stock go down today? - MarketBeatAbbVie (NYSE:ABBV) Price Target Increased to $220.00 by Analysts at BMO ...

CouponFollow Extension

$220.00
OFF

BMO Capital Markets Issues Pessimistic Forecast For …

1 week from now

marketbeat.com

$228.00
OFF

BMO Capital Markets Lowers AbbVie (NYSE:ABBV) Price Target To …

1 week from now

2 days ago · AbbVie (NYSE:ABBV – Free Report) had its price target cut by BMO Capital Markets from $228.00 to $208.00 in a report released on Tuesday,Benzinga reports. They currently …

americanbankingnews.com

$226.00
OFF

ABBV News Today | Why Did AbbVie Stock Go Down Today?

1 week from now

Nov 11, 2024 · Citigroup dropped their target price on shares of AbbVie from $226.00 to $215.00 and set a "buy" rating on the stock in a research report on Tuesday. BMO Capital Markets …

marketbeat.com

$208
OFF

AbbVie Price Target Lowered To $208 From $228 At BMO Capital

1 week from now

6 days ago · Nov. 12, 2024, 07:45 AM. BMO Capital analyst Evan Seigerman lowered the firm’s price target on AbbVie (ABBV) to $208 from $228 and keeps an Outperform rating on the …

businessinsider.com

26%
OFF

AbbVie Stock Target Cut, Rating Continued On Trial Results

1 week from now

6 days ago · ABBV. -0.26%. On Tuesday, BMO Capital Markets adjusted its outlook on AbbVie (NYSE: ABBV) shares by reducing the price target to $208 from the previous $228. The firm …

investing.com

$220
OFF

AbbVie Price Target Raised To $220 From $214 At BMO Capital

1 week from now

Oct 18, 2024 · BMO Capital raised the firm’s price target on AbbVie to $220 from $214 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results …

yahoo.com

$208
OFF

ABBV Stock Quote Price And Forecast | CNN

1 week from now

View AbbVie, Inc. ABBV stock quote prices, financial information, real-time forecasts, and company news from CNN. ... lowered to $208 from $228 at BMO Capital by TipRanks …

cnn.com

$228.00
OFF

BMO Capital Markets Has Lowered Expectations For AbbVie …

1 week from now

4 days ago · AbbVie (NYSE:ABBV – Get Free Report) had its price target decreased by analysts at BMO Capital Markets from $228.00 to $208.00 in a research report issued on …

etfdailynews.com

$228
OFF

AbbVie's Schizophrenia Failure Disappoints But Analysts Show

1 week from now

5 days ago · BMO Capital Markets writes, “AbbVie core I&I thesis intact, but this one stings.” The analyst has lowered the price target from $228 to $208 and maintains the Outperform rating, …

benzinga.com

$228.00
OFF

BMO Capital Markets Issues Pessimistic Forecast For AbbVie …

1 week from now

4 days ago · AbbVie (NYSE:ABBV – Get Free Report) had its price target lowered by equities researchers at BMO Capital Markets from $228.00 to $208.00 in a research report issued on …

defenseworld.net

$203.83
OFF

AbbVie (ABBV) Stock Forecast And Price Target 2024 - MarketBeat

1 week from now

3 days ago · According to the 20 analysts' twelve-month price targets for AbbVie, the average price target is $203.83. The highest price target for ABBV is $225.00, while the lowest price …

marketbeat.com

$170
OFF

What Is The Current Price Target And Forecast For AbbVie (ABBV)

1 week from now

4 days ago · The forecasts for AbbVie Inc. (ABBV) range from a low of $170 to a high of $240. The average price target represents a increase of $20.83 from the last closing price of …

zacks.com

$220.00
OFF

AbbVie (NYSE:ABBV) Price Target Increased To $220.00 By Analysts …

1 week from now

Oct 17, 2024 · AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Thursday, July 25th. The company reported $2.65 earnings per share (EPS) for the quarter, …

marketbeat.com

FAQs about BMO Capital Markets Issues Pessimistic Forecast for … Coupon?

What are the forecasts for AbbVie Inc (abbv)?

The forecasts for AbbVie Inc. (ABBV) range from a low of $170 to a high of $225. The average price target represents a increase of $7.72 from the last closing price of $187.85. The current UPSIDE for AbbVie Inc. (ABBV) is 7.72% ...

Should you buy AbbVie (abbv)?

Out of the 18 analysts, 4 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for ABBV. According to the 18 analysts' twelve-month price targets for AbbVie, the average price target is $198.47. The highest price target for ABBV is $225.00, while the lowest price target for ABBV is $150.00. ...

Is AbbVie a good stock to buy?

AbbVie's strong portfolio of pharmaceutical products, including Humira, Skyrizi, Rinvoq, and Imbruvica, provides diversified revenue streams. Recent analyst ratings have been overwhelmingly positive, with multiple firms raising price targets and issuing buy ratings on AbbVie. ...

Why did AbbVie increase its profit forecast for 2024?

REUTERS/Andrew Kelly/File Photo Purchase Licensing Rights July 25 (Reuters) - AbbVie (ABBV.N) increased its profit forecast for 2024 on Thursday after reporting strong sales of immunology drugs and quarterly results that exceeded Wall Street expectations, sending its shares to a record high. ...

Is AbbVie (ABV) stock overvalued?

The company's PE ratio of 57.35 and PEG ratio of 2.65 suggest that the stock may be overvalued compared to industry peers. AbbVie's beta of 0.63 indicates lower volatility compared to the market, potentially limiting short-term trading opportunities. ...

Why does AbbVie have a high debt-to-equity ratio?

AbbVie's consistent investment in research and development ensures a pipeline of innovative drugs that could drive future growth. AbbVie's high debt-to-equity ratio of 8.51 may pose a risk in case of economic downturns or financial instability. ...